Optimizing the treatment of BRAF mutant melanoma

Selective inhibitors of the kinases BRAF and MEK for the treatment of patients with otherwise refractory BRAF mutant melanoma have demonstrated impressive efficacy, and combination treatment with these agents may prove to be even more effective. However, these drugs are not curative, mainly because...

Descripción completa

Detalles Bibliográficos
Autor principal: Settleman, Jeff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062054/
https://www.ncbi.nlm.nih.gov/pubmed/25031620
http://dx.doi.org/10.1186/gm547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062054/
https://www.ncbi.nlm.nih.gov/pubmed/25031620
http://dx.doi.org/10.1186/gm547

Ejemplares similares